【EIZO】Full-Year Earnings Guidance Revision | Sales ¥81,300 million (+2.9%)

Performance Overview

Eizo has revised its full-year earnings forecast for the fiscal year ending March 2026, raising projected sales to ¥81,300 million (up 2.9% from previous forecast). Sales are steadily recovering in Europe, North America, and China. Japanese sales were sluggish due to the hospital management environment but are expected to surpass previous estimates by capturing end-of-term demand. Operating income and ordinary income are also projected to exceed previous forecasts. However, an inventory valuation loss of approximately ¥400 million related to stock of legacy models is scheduled to be recorded. In the fourth quarter, gains on sale of investment securities of about ¥6,600 million are anticipated.

Future Outlook and Impact on Shareholders

Going forward, Eizo will accelerate the reduction of inventory of legacy models and the transition to new models to improve profitability. The dividend remains unchanged at the end of May 8, 2025, with a payout of ¥55 per share, maintaining stable shareholder returns. For investors, the outlook of sales recovery and profit improvement is promising, with potential for stock price appreciation.